4-(3-(4-methoxyphenyl)-1,2,4-oxadiazol-5-yl)phenol | 1136832-89-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-(3-(4-methoxyphenyl)-1,2,4-oxadiazol-5-yl)phenol
• 英文别名: 4-[3-(4-methoxyphenyl)-1,2,4-oxadiazol-5-yl]phenol
• CAS: 1136832-89-7
• 化学式: C₁₅H₁₂N₂O₃
• 分子量: 268.272
• InChiKey: BZDBPBCAZBLHCJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  68.4
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  5-(4-(benzyloxy)phenyl)-3-(4-methoxyphenyl)-1,2,4-oxadiazole 在 钯 氢气 、 silica gel 、 乙酸乙酯 作用下， 以 甲醇 、 四氢呋喃 为溶剂， 反应 95.0h， 以to give the product (3 mg, 9%) as a white solid的产率得到4-(3-(4-methoxyphenyl)-1,2,4-oxadiazol-5-yl)phenol
  参考文献：
  名称：

  Antibacterial compounds and methods of using same

  摘要：

  本发明的实施例提供了新型抗菌剂，其靶向青霉素结合蛋白或其他重要的细胞靶点。本文所述化合物抑制细菌的生长（繁殖等）的方法也被提供。各种实施例对革兰氏阳性菌表现出活性，例如某些肠球菌和金黄色葡萄球菌菌株。

  公开号：

  US09045442B2

文献信息

• ANTIBACTERIAL COMPOUNDS AND METHODS OF USING SAME
  申请人：Mobashery Shahriar

  公开号：US20100261673A1

  公开（公告）日：2010-10-14

  Embodiments of the present invention provide novel antibacterials that target penicillin-binding proteins or other important cellular targets. Methods for inhibiting growth (reproduction, etc.) of bacteria using compounds described herein are also provided. Various embodiments exhibit activity against gram positive bacteria, such as certain strains of Entercoccus and Staphylococcus aureus.

  本发明的实施例提供了针对青霉素结合蛋白或其他重要细胞靶标的新型抗菌剂。本文描述的化合物用于抑制细菌的生长（繁殖等）的方法也得到提供。各种实施例对革兰氏阳性细菌表现出活性，如某些肠球菌和金黄色葡萄球菌菌株。
• [EN] ANTIBACTERIAL COMPOUNDS AND METHODS OF USING SAME<br/>[FR] COMPOSÉS ANTIBACTÉRIENS ET LEURS PROCÉDÉS D'UTILISATION
  申请人：UNIV NOTRE DAME DU LAC

  公开号：WO2009041972A1

  公开（公告）日：2009-04-02

  Embodiments of the present invention provide novel antibactehals that target penicillin-binding proteins or other important cellular targets. Methods for inhibiting growth (reproduction, etc.) of bacteria using compounds described herein are also provided. Various embodiments exhibit activity against gram positive bacteria, such as certain strains of Entercoccus and Staphylococcus aureus.

  本发明实施例提供了针对青霉素结合蛋白或其他重要细胞靶点的新型抗菌剂。本文描述的化合物用于抑制细菌的生长（繁殖等）的方法也提供了。各种实施例对革兰氏阳性细菌表现出活性，例如某些肠球菌和金黄色葡萄球菌菌株。
• Compounds for the treatment of Clostridium difficile infection
  申请人：University of Notre Dame du Lac

  公开号：US11168062B2

  公开（公告）日：2021-11-09

  Clostridium difficile infection (CDI) is a public health threat that results in 14,000 annual deaths in the United States. Challenges involve the production of CDI spores that can remain dormant for years and the production of toxins that damage the gut. Current therapies for CDI include vancomycin and metronidazole, but neither inhibits spore or toxin production. Thus, recurrence of infection occurs in 25% of patients and there are no antibiotics that are effective for multiple recurrences. We describe oxadiazoles with activity against C. difficile, including the highly virulent NAP1/027 strain with increased production of toxins A and B, as well as the additional binary toxin. Oxadiazole 2 is poorly absorbed, thus advantageously achieving high concentrations in the gut. The compound targets peptidoglycan synthesis and inhibits vegetative cells, spores, and toxin production.

  艰难梭菌感染（CDI）是一种公共卫生威胁，在美国每年造成 14,000 人死亡。其挑战在于 CDI 孢子的产生，这种孢子可保持休眠状态数年之久，并产生损害肠道的毒素。目前治疗 CDI 的药物包括万古霉素和甲硝唑，但这两种药物都不能抑制孢子或毒素的产生。因此，25% 的患者会出现感染复发，而目前还没有对多次复发有效的抗生素。我们介绍了对艰难梭菌具有活性的噁二唑类药物，包括毒性极强的 NAP1/027 菌株，其毒素 A 和毒素 B 以及额外的二元毒素的产量均有所增加。噁二唑 2 的吸收性很差，因此在肠道中具有高浓度的优势。该化合物靶向肽聚糖合成，抑制无性细胞、孢子和毒素的产生。
• COMPOUNDS FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE INFECTION
  申请人：University of Notre Dame du Lac

  公开号：US20190210984A1

  公开（公告）日：2019-07-11

  Clostridium difficile infection (CDI) is a public health threat that results in 14,000 annual deaths in the United States. Challenges involve the production of CDI spores that can remain dormant for years and the production of toxins that damage the gut. Current therapies for CDI include vancomycin and metronidazole, but neither inhibits spore or toxin production. Thus, recurrence of infection occurs in 25% of patients and there are no antibiotics that are effective for multiple recurrences. We describe oxadiazoles with activity against C. difficile, including the highly virulent NAP1/027 strain with increased production of toxins A and B, as well as the additional binary toxin. Oxadiazole 2 is poorly absorbed, thus advantageously achieving high concentrations in the gut. The compound targets peptidoglycan synthesis and inhibits vegetative cells, spores, and toxin production.
• US9045442B2
  申请人：——

  公开号：US9045442B2

  公开（公告）日：2015-06-02